{"title":"Serum Protein Glycopatterns as Biomarkers for Machine Learning Diagnosis of Major Depressive Disorder.","authors":"Shiyi Wang, Jian Shu, Hanjie Yu, Yue Shi, Chen Zhang, Xinyuan Hu, Zheng Li","doi":"10.1093/glycob/cwag080","DOIUrl":null,"url":null,"abstract":"<p><p>The diagnosis of major depressive disorder (MDD) currently relies on subjective clinical assessment, underscoring the need for objective biomarkers. Glycosylation, a common post-translational modification, is involved in neuroinflammation and immune regulation, both implicated in MDD pathogenesis. This study aimed to identify serum protein glycopatterns as biomarkers for MDD diagnosis and severity stratification. Serum samples from 150 individuals, including healthy volunteers (HV, n = 38), mild-to-moderate MDD (M-MDD, n = 52), and severe MDD (S-MDD, n = 60), were analyzed using lectin microarrays. Thirty-six lectins showed significantly altered binding signals that indicating widespread glycosylation changes between HV, M-MDD, and S-MDD. These features were used to train seven machine-learning models, among which K-nearest neighbours (KNN) performed best, achieving 95.3% ± 2.7% accuracy and an AUC (Micro) of 0.990 ± 0.010 in a nested 5-fold cross-validation framework. In a blinded cohort (n = 71), the KNN model showed accuracies of 0.831, 0.662, and 0.831 for MDD, M-MDD, and S-MDD, respectively. SHAP analysis identified key lectins contributing to classification. These results demonstrated that serum glycopatterns combined with machine learning provided a promising objective tool for MDD diagnosis and severity assessment.</p>","PeriodicalId":12766,"journal":{"name":"Glycobiology","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glycobiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/glycob/cwag080","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The diagnosis of major depressive disorder (MDD) currently relies on subjective clinical assessment, underscoring the need for objective biomarkers. Glycosylation, a common post-translational modification, is involved in neuroinflammation and immune regulation, both implicated in MDD pathogenesis. This study aimed to identify serum protein glycopatterns as biomarkers for MDD diagnosis and severity stratification. Serum samples from 150 individuals, including healthy volunteers (HV, n = 38), mild-to-moderate MDD (M-MDD, n = 52), and severe MDD (S-MDD, n = 60), were analyzed using lectin microarrays. Thirty-six lectins showed significantly altered binding signals that indicating widespread glycosylation changes between HV, M-MDD, and S-MDD. These features were used to train seven machine-learning models, among which K-nearest neighbours (KNN) performed best, achieving 95.3% ± 2.7% accuracy and an AUC (Micro) of 0.990 ± 0.010 in a nested 5-fold cross-validation framework. In a blinded cohort (n = 71), the KNN model showed accuracies of 0.831, 0.662, and 0.831 for MDD, M-MDD, and S-MDD, respectively. SHAP analysis identified key lectins contributing to classification. These results demonstrated that serum glycopatterns combined with machine learning provided a promising objective tool for MDD diagnosis and severity assessment.
重度抑郁症(MDD)的诊断目前依赖于主观的临床评估,强调了对客观生物标志物的需求。糖基化是一种常见的翻译后修饰,参与神经炎症和免疫调节,两者都与MDD的发病机制有关。本研究旨在确定血清蛋白糖型作为重度抑郁症诊断和严重程度分层的生物标志物。使用凝集素芯片分析了150名健康志愿者(HV, n = 38)、轻至中度重度抑郁症(M-MDD, n = 52)和重度重度抑郁症(S-MDD, n = 60)的血清样本。36种凝集素的结合信号显著改变,表明HV、M-MDD和S-MDD之间存在广泛的糖基化变化。这些特征用于训练7个机器学习模型,其中k近邻(KNN)表现最好,在嵌套的5倍交叉验证框架中达到95.3%±2.7%的准确率和0.990±0.010的AUC (Micro)。在一个盲法队列(n = 71)中,KNN模型对MDD、M-MDD和S-MDD的准确率分别为0.831、0.662和0.831。SHAP分析确定了有助于分类的关键凝集素。这些结果表明,结合机器学习的血糖模式为重度抑郁症的诊断和严重程度评估提供了一个有希望的客观工具。
期刊介绍:
Established as the leading journal in the field, Glycobiology provides a unique forum dedicated to research into the biological functions of glycans, including glycoproteins, glycolipids, proteoglycans and free oligosaccharides, and on proteins that specifically interact with glycans (including lectins, glycosyltransferases, and glycosidases).
Glycobiology is essential reading for researchers in biomedicine, basic science, and the biotechnology industries. By providing a single forum, the journal aims to improve communication between glycobiologists working in different disciplines and to increase the overall visibility of the field.